Loading…
Korean biotech making peptide-based ingredients used in cosmeceuticals and skincare products sold under partner K-beauty brands.
Korean biotech making peptide-based ingredients used in cosmeceuticals and skincare products sold under partner K-beauty brands.
Moat: narrow (IP / patents, process know-how). Peptide synthesis patents and formulation know-how used across many partner skincare brands.
Headquarters: Anyang, South Korea · Founded: 2000 · Employees: 201
Size Caregen (214370.KS) is a South Korea Materials company (Chemicals: Major Diversified) with a market value of $1.01B, the 230th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩28,150 on 6 Nov 2026.
Performance Over six months the shares fell 73.3%, against -26.4% for the median peer and -24.5% for the South Korea market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue fell 7.6% over the last twelve months (peer median +1.2%); the operating margin is 24.2% (peer median 12.3%).
Valuation It trades at 22.6× forward earnings against a peer median of 20.8× (6th most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 35% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +31 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.5 points below its cost of capital (7.8% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩74.9B | ₩72.8B | ₩82.6B | ₩79.2B | ₩69.1B |
| Revenue growth | — | -12% | +4% | +15% | — |
| Gross profit | ₩50.8B | ₩50.0B | ₩53.0B | ₩56.8B | ₩50.7B |
| EBITDA | ₩23.3B | ₩25.6B | ₩39.2B | ₩44.6B | ₩35.7B |
| Net income | ₩22.9B | ₩20.1B | ₩32.3B | ₩39.9B | ₩27.3B |
| Free cash flow | ₩22.2B | ₩14.7B | -₩52.4B | ₩20.4B | ₩29.6B |
| Capital expenditure | ₩4.71B | ₩4.92B | ₩67.0B | ₩9.70B | ₩3.03B |
| Total debt | ₩0 | ₩0 | ₩0 | ₩0 | ₩0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Caregen 214370.KS | $1.01B | -73% | -8% | 24% | 22.6× | 35.2% |
| PharmaResearch 214450.KS | $1.79B | -25% | +34% | 39% | 12.4× | -14.2% |
| Kolmar Korea 161890.KS | $1.89B | +23% | +13% | 10% | 13.0× | -0.9% |
| Cosmax 192820.KS | $2.13B | +21% | +16% | 8% | 16.6× | n/a |
| Croda International CRDA.L | $6.88B | +31% | +3% | 16% | 23.3× | 19.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 214370.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -36.7% | -10.0% | 2nd lowest of 21 |
| 6-month return | -73.3% | -26.4% | lowest of 21 |
| Distance from 52-week high | -81.7% | -45.0% | lowest of 21 |
| Revenue growth (TTM) | -7.6% | +1.2% | 6th lowest of 21 |
| Operating margin | 24.2% | 12.3% | 3rd highest of 21 |
| Forward P/E | 22.6× | 20.8× | 6th most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 35.2% | 9.1% | 3rd most demanding of 15 |
| Growth delivered (Del g) | +3.8% | +9.5% | 5th lowest of 15 |
| Hurdle (Req g minus delivered) | +31.3 pp | -2.1 pp | most demanding of 15 |
| ROIC minus cost of capital | -0.5 pp | -2.1 pp | 9th highest of 21 |
| EV / EBITDA | 57.5× | 9.3× | 2nd most expensive of 10 |
| Net debt / EBITDA | -1.5× | 0.1× | 4th least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Caregen 214370.KS | South Korea | $1.01B | -73% | -8% | 24% | 22.6× | 35.2% | +3.8% |
| Victrex VCT.L | United Kingdom | $1.04B | +54% | -1% | 14% | 21.7× | 15.7% | +1.9% |
| Jiangsu Zhengdan Chemical Industry 300641.SZ | China | $981M | -28% | -30% | 17% | n/a | 8.8% | +11.6% |
| Dalian Bio-Chem 603360.SS | China | $1.05B | -55% | 0% | 16% | 23.5× | 9.5% | +18.4% |
| Jubilant Ingrevia JUBLINGREA.NS | India | $966M | -24% | +15% | 10% | 21.1× | 27.3% | +44.9% |
| Zhejiang Huangma Technology 603181.SS | China | $935M | -30% | +7% | 17% | 14.5× | n/a | n/a |
| Guangzhou Sanfu Newmaterials Technology 688359.SS | China | $870M | -41% | +8% | -7% | n/a | n/a | n/a |
| Nippon Soda 4041.T | Japan | $1.19B | -5% | -1% | 10% | 11.1× | 3.5% | +1.8% |
| Suzhou Highfine Biotech 301393.SZ | China | $865M | -8% | +36% | 17% | 32.3× | n/a | n/a |
| Raghav Productivity Enhancers RPEL.NS | India | $864M | +133% | +38% | 28% | n/a | n/a | n/a |
| Hubei Jianghan New Materials 603281.SS | China | $1.20B | -30% | +8% | 17% | 20.5× | 4.8% | +6.3% |
| CNSIG Inner Mongolia Chemical Industry 600328.SS | China | $1.21B | -32% | -20% | -7% | n/a | n/a | n/a |
| Polyrocks Chemical 688669.SS | China | $831M | +40% | -8% | -6% | n/a | 35.9% | +15.2% |
| Sanyo Chemical Industries 4471.T | Japan | $823M | +24% | 0% | 10% | 10.5× | -5.1% | -2.5% |
| Jiangxi Hungpai New Material 605366.SS | China | $821M | -47% | +2% | -11% | 236.0× | n/a | n/a |
| Xinxiang Richful Lube Additive 300910.SZ | China | $1.26B | -38% | +12% | 16% | 11.6× | 0.6% | +32.5% |
| Jinan Acetate Chemical 4763.TW | Taiwan | $1.26B | -3% | -36% | 46% | 7.3× | -17.4% | +41.2% |
| Lanxess LXS.DE | Germany | $1.27B | -30% | -10% | -1% | n/a | 17.9% | -1.5% |
| Hanchem 014680.KS | South Korea | $1.30B | -40% | +15% | 17% | 11.1× | 4.7% | +7.4% |
| Xinyaqiang Silicon Chemistry 603155.SS | China | $788M | -6% | +6% | 10% | 37.0× | 31.1% | +3.9% |
| Hubei Chaozhuo Aviation Technology 688237.SS | China | $776M | +6% | -1% | 1% | 41.5× | 45.3% | +26.0% |